{"count": 1, "results": [{"_id": "28556385", "pmid": 28556385, "title": "Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.", "journal": "Pediatr Dermatol", "authors": ["Bayart CB", "Tamburro JE", "Vidimos AT", "Wang L", "Golden AB"], "date": "2017-07-01T00:00:00Z", "doi": "10.1111/pde.13177", "meta_date_publication": "2017 Jul", "meta_volume": "34", "meta_issue": "4", "meta_pages": "413-421", "score": 50057.41, "text_hl": "There was no significant difference in the overall rate of adverse effects (p = 0.10), although 11% of @SPECIES_9606 @@@patients@@@ treated with @CHEMICAL_Propranolol @CHEMICAL_MESH:D011433 @@@propranolol@@@ experienced @<m>DISEASE_Adjustment_Disorders</m> @DISEASE_MESH:D000275 @@@reactive airway symptoms@@@, whereas this was not seen in any of the @SPECIES_9606 @@@patients@@@ treated with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB. Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. Pediatr Dermatol. 2017 Jul;34(4):413-421. PMID: 28556385", "BibTeX": "@article{28556385, title={Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.}, author={Bayart CB and Tamburro JE and Vidimos AT and Wang L and Golden AB}, journal={Pediatr Dermatol}, volume={34}, number={4}, pages={413-421}}"}}]}